Department of Neurology, The Third Affiliated Hospital, Sun Yat-sen University, 600 Tianhe Road, Guangzhou, Guangdong 510630, China.
J Neuroimmunol. 2011 Jun;235(1-2):1-8. doi: 10.1016/j.jneuroim.2011.04.006. Epub 2011 May 11.
Multiple sclerosis (MS) is the most common inflammatory demyelinating disease of the central nervous system (CNS). Although there are several approved drugs for MS, not all patients respond optimally to these drugs. More effective, well-tolerated therapeutic strategies for MS are necessary, either through the development of new medication or combination of existing ones. Minocycline is a traditional antibiotic with profound anti-inflammatory and neuroprotective effects and good tolerance for long-term use. The encouraging results from the animal model and clinical experiments on minocycline make it a promising candidate for MS treatment whether used alone or combined with other drugs. In this review, we summarized the pharmacological actions of minocycline and focused on its therapeutic effects and safety in experimental autoimmune encephalomyelitis (EAE) and MS. The data obtained here showed that minocycline would be an effective and safe therapy for MS.
多发性硬化症（MS）是中枢神经系统（CNS）最常见的炎症性脱髓鞘疾病。尽管有几种批准用于 MS 的药物，但并非所有患者对这些药物都能达到最佳反应。需要更有效、耐受性更好的 MS 治疗策略，无论是通过开发新药物还是组合使用现有药物。米诺环素是一种具有深远抗炎和神经保护作用的传统抗生素，并且长期使用耐受性良好。米诺环素在动物模型和临床实验中的令人鼓舞的结果使其成为治疗 MS 的有前途的候选药物，无论是单独使用还是与其他药物联合使用。在这篇综述中，我们总结了米诺环素的药理学作用，并重点介绍了其在实验性自身免疫性脑脊髓炎（EAE）和 MS 中的治疗效果和安全性。这里获得的数据表明，米诺环素将是一种治疗 MS 的有效且安全的疗法。
